REPLIGEN CORP Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions
REPLIGEN CORP (RGEN) reported Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions of $10.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions · last filed 2026-02-26
- REPLIGEN CORP unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2025 was $10.00K, a 50.00% decline from fiscal 2024.
- REPLIGEN CORP unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2024 was $20.00K, a 62.26% decline from fiscal 2023.
- REPLIGEN CORP unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2023 was $53.00K, a 17.19% decline from fiscal 2022.
- REPLIGEN CORP unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2022 was $64.00K, a 87.20% decline from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions 9 month | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions 12 month | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions 12 month as first filed |
|---|---|---|---|
| 2025-12-31 | $10.00K 10-K · filed 2026-02-26 | ||
| 2024-12-31 | $20.00K 10-K · filed 2026-02-26 | -$20.00K 10-K · filed 2025-03-14 | |
| 2023-12-31 | $53.00K 10-K · filed 2025-03-14 | ||
| 2022-12-31 | $64.00K 10-K/A · filed 2024-11-18 | ||
| 2021-12-31 | $500.00K 10-K · filed 2023-02-22 | ||
| 2020-12-31 | $337.00K 10-K · filed 2022-02-17 | ||
| 2019-12-31 | $16.00K 10-K · filed 2021-02-24 | ||
| 2015-09-30 | $125.00K 10-Q · filed 2015-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |